The resulting SS18-SSX fusion oncoprotein participates in both positive and negative regulation of gene expression, which subsequently leads to the activation of oncogenic pathways and the inhibition of tumour suppressor pathways (Nielsen et al., 2015). This evidence concerns the gene SSX2 and neoplasm.